Bicara Therapeutics (NASDAQ:BCAX) Raised to “Hold” at The Goldman Sachs Group

Bicara Therapeutics (NASDAQ:BCAX) was upgraded by The Goldman Sachs Group to a “hold” rating in a report released on Tuesday,Zacks.com reports.

A number of other research analysts have also recently commented on the company. Wells Fargo & Company upped their target price on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th. HC Wainwright upped their target price on Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Wedbush reaffirmed an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Finally, Bank of America began coverage on Bicara Therapeutics in a research note on Wednesday, March 25th. They set a “buy” rating and a $35.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $30.27.

Bicara Therapeutics Stock Performance

BCAX opened at $20.97 on Tuesday. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -7.54 and a beta of -0.57. The stock’s 50 day moving average price is $20.92 and its 200-day moving average price is $18.15. Bicara Therapeutics has a one year low of $7.80 and a one year high of $24.25.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, analysts predict that Bicara Therapeutics will post -3.17 earnings per share for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In related news, CFO Ivan Hyep sold 13,555 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $18.22, for a total value of $246,972.10. Following the transaction, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,648,368.10. This represents a 8.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Claire Mazumdar sold 36,766 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $19.17, for a total value of $704,804.22. Following the completion of the transaction, the chief executive officer directly owned 339,392 shares in the company, valued at approximately $6,506,144.64. This trade represents a 9.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 174,310 shares of company stock worth $3,459,283 in the last ninety days. 15.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc grew its stake in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Bicara Therapeutics in the fourth quarter worth approximately $45,000. Larson Financial Group LLC lifted its holdings in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after buying an additional 3,595 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.